Practical Derm

🩺🎤📸ON SCENE: Photos from the Skin Cancer Champions Patient Advocacy Summit in Boston.

📢🚨NEW APPROVAL: The FDA has approved ILUMYA® (tildrakizumab-asmn) for US HCPs for adults with active psoriatic arthritis, expanding its indication beyond moderate-to-severe plaque psoriasis ➡️ ow.ly/V4ov5102rqs #ILUMYA #Tildrakizumab #Biologics #ClinicalTrials #PsoriaticArthritis #Dermatology

🔬 📊 💊 ESTROGEN AND PORPHYRIA CUTANEA TARDA RISK: A nationwide Danish study involving more than 44,000 women found that estrogen-containing therapy was associated with approximately twice the odds of incident PCT. 📊 Oral estrogen: adjusted OR, 2.4 💊 Nonoral estrogen: No statistically significant association identified. Read more ➡️ ow.ly/7bqu5102igV #Dermatology #PorphyriaCutaneaTarda #WomensHealth #HormoneTherapy #ClinicalResearch

📊 2-YEAR BIMEKIZUMAB DATA: A new multicenter study in JAAD evaluated bimekizumab in 152 adults with plaque psoriasis. Key findings included: 🔹 71.1% achieved PASI 100 🔹 81.6% achieved IGA 0/1 Read more ➡️ ow.ly/jjs25101cAO #Dermatology #Psoriasis #Bimekizumab #ClinicalResearch

📊🔬 VALOR DATA UPDATE: A secondary analysis of the VALOR trial found that brepocitinib 30 mg improved cutaneous disease activity, itch, and skin-related quality of life as early as week 4 ➡️ ow.ly/Xc2I5101vMr #Dermatology #Dermatomyositis #ClinicalTrials #JAMADermatology #MedicalResearch #Brepocitinib #DermatologyResearch

📊🔍👨‍⚕️STUDY 304 RESULTS: Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia ➡️ ow.ly/5pf05100Hm5

📢🩺NEW: Patients with #psoriasis treated with interleukin (IL)-23 inhibitors had a lower observed incidence of psoriatic arthritis (PsA) than those receiving Janus kinase (JAK) inhibitors or IL-17 inhibitors ➡️ ow.ly/8VgQ5100GII #Dermatology #SkinHealth #Skin #ClinicalResearch

💆‍♂️💆‍♀️APPLYING PRESSURE WORKS - Device-free auricular #acupressure improved clinical outcomes and reduced inflammatory #biomarkers in patients with #rosacea receiving standard first-line treatment, according to findings from a trial published in JAMA Dermatology. Read more ➡️ ow.ly/x9Ro5100G8N

🩺 NEW: The National Rosacea Society has awarded two $12,500 grants to advance research into rosacea pathogenesis ➡️ ow.ly/QZiE5100gpT #Dermatology #Rosacea #ClinicalResearch #SkinHealth

🚨 The October issue of Practical Dermatology is now online! - Explore The Evolving Landscape of Atopic Dermatitis, featuring expert perspectives on treatment options, patient-reported outcomes, and emerging considerations in care➡️ ow.ly/tVgA50ZZuPQ #PracticalDermatology #AtopicDermatitis #Dermatology #SkinHealth #DermatologyResearch

🎙️👨‍⚕️NEW DISEASE DEEP DIVE: Walter Liszewski, MD, and Naiem Issa, MD, discuss how to diagnose chronic spontaneous urticaria, avoid unnecessary testing, and apply updated treatment recommendations, including newer systemic therapies.✨💉 🎧 Listen here ➡️ ow.ly/xH4O50ZYNyx

📊👀NEW DATA: The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2026 Fall Clinical Dermatology Conference ➡️ ow.ly/wfkU50ZYJz5

👨‍⚕️👩‍⚕️👨‍⚕️👩‍⚕️📊PANEL PROPOSES MOLLUSCUM TREATMENT ALGORITHM: A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making ➡️ ow.ly/5jBq50ZYxS7

NEW ACQUISITION: Galderma to Acquire ZO Skin Health for $1.5 Billion: Galderma announced an agreement to acquire ZO Skin Health for $1.5 billion, a move it says will expand its dermatological skincare business and strengthen its presence in the physician-dispensed skincare market. Read more ➡️ ow.ly/UZfy50ZXS8W

📊🩺 NEW DATA: Researchers have announced new phase 1b data for SYX-5219, an investigational oral PKM2 modulator, which showed improvements in atopic dermatitis severity and itch over 6 weeks ➡️ ow.ly/bsJV50ZXjwb #SkinHealth #PKM2Modulator #MedicalResearch #ClinicalTrials #Dermatology #AtopicDermatitis #ClinicalResearch

📊 🔍 ICYMI: Dr. Shawn Kwatra analyzes new data from the phase 3b ADtouch study for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas ➡️ ow.ly/NYCN50ZWQFw #AtopicDermatitis #SkinHealth #SkinDisease #ClinicalResearch

👀 📊GAPS IN ATOPIC DERM SKIN MODELS: A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD) ➡️ ow.ly/g8Bw50ZWysc #SkinResearch #Dermatology #SkinHealth #AtopicDermatitis

🎤👨‍⚕️📊NEW: Study investigator Dr. Shawn Kwatra talked with Practical Dermatology about new Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) and how it may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas 👉 ow.ly/u3XV50ZVtve

🚨🆕 The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines 🔬👉ow.ly/BBbn50ZVxgU

🏆 NEWS: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) ZORYVE® (roflumilast) HCP cream 0.15% has received Marie Claire’s inaugural Best Prescription Skin Solution Award ➡️ ow.ly/zrCS50ZV8cU #Dermatology #AtopicDermatitis #Eczema #ZORYVE #Dermatology